<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="196">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01849562</url>
  </required_header>
  <id_info>
    <org_study_id>ACH102-007</org_study_id>
    <nct_id>NCT01849562</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Efficacy of 12-weeks of Sovaprevir, ACH-3102 and Ribavirin in Treatment-naive GT-1 HCV Subjects</brief_title>
  <official_title>A Phase 2a Trial to Evaluate the Safety, Tolerability and Efficacy of 12 Weeks of Sovaprevir, ACH-0143102 and Ribavirin in Treatment-Naive Subjects With Chronic Hepatitis C Genotype-1 Viral Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Achillion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Achillion Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and efficacy of 12 weeks
      of treatment with sovaprevir, ACH-0143102 and ribavirin in GT1, treatment-naive, HCV
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of Sustained Virologic Response 4 Weeks (SVR4) After the Completion of Treatment.</measure>
    <time_frame>Four weeks after the completion of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Incidence of SVR4 after the completion of dosing, reported as HCV RNA less than the lower limit of quantification (&lt;LLOQ), in subjects who received active treatment (sovaprevir and ACH-0143102 in combination with ribavirin) as compared to those who received placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of 12 Weeks of Sovaprevir and 3102 in Combination With Ribavirin in Subjects With Chronic Hepatitis C Genotype 1 Viral Infection.</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To determine safety and tolerability of 12 weeks of sovaprevir/ACH-0143102/RBV in subjects with chronic hepatitis C genotype 1, the following criteria will be used: the number of subjects with discontinuations due to AEs, treatment emergent G3/G4 AEs, treatment emergent G3/G4 laboratory abnormalities, clinically significant ECGs.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Sovaprevir 200 mg, ACH-3102 150/50 mg, RBV 1000-1200mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sovaprevir 200 mg QD + ACH-3102 150 mg loading dose on Day 1 followed by 50 mg QD + RBV weight-based 1000-1200mg QD for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sovaprevir 400 mg, ACH-3102 150/50mg,RBV1000-1200mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sovaprevir 400 mg QD + ACH-3102 150 mg loading dose on Day 1 followed by 50 mg QD + RBV weight-based 1000-1200mg QD for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for Sovaprevir capsule QD + placebo for ACH-3102 150 mg loading dose on Day 1 followed by 50 mg capsule QD + placebo for weight-based RBV QD for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sovaprevir</intervention_name>
    <description>NS3/4A protease inhibitor</description>
    <arm_group_label>Sovaprevir 200 mg, ACH-3102 150/50 mg, RBV 1000-1200mg</arm_group_label>
    <arm_group_label>Sovaprevir 400 mg, ACH-3102 150/50mg,RBV1000-1200mg</arm_group_label>
    <other_name>ACH-0141625</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH-3102</intervention_name>
    <description>NS5A inhibitor</description>
    <arm_group_label>Sovaprevir 200 mg, ACH-3102 150/50 mg, RBV 1000-1200mg</arm_group_label>
    <arm_group_label>Sovaprevir 400 mg, ACH-3102 150/50mg,RBV1000-1200mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RBV</intervention_name>
    <arm_group_label>Sovaprevir 200 mg, ACH-3102 150/50 mg, RBV 1000-1200mg</arm_group_label>
    <arm_group_label>Sovaprevir 400 mg, ACH-3102 150/50mg,RBV1000-1200mg</arm_group_label>
    <other_name>Ribavirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and Females between ages 18 and 65

          -  Chronic HCV infection

          -  HCV genotype 1

          -  HCV RNA &gt; 10,000 IU/mL at screening.

          -  Female patients must be willing to use two effective methods of contraception, one of
             which must be barrier method, during dosing period and six months after last dose of
             ribavirin. Females of childbearing potential must have a negative pregnancy test at
             screening and baseline.

          -  Male patients must be willing to use an effective barrier method of contraception
             throughout the dosing period and for six months.

          -  Signed and dated written informed consent form.

          -  Willing to participate in all study activities and all study requirements (including
             effective contraception) during study period.

          -  Treatment na√Øve subjects defined as subjects who have never received pegylated
             interferon, RBV, or a direct-acting anti-viral agent for the treatment of chronic HCV
             infection.

          -  A liver biopsy within the last 3 years without evidence of cirrhosis.

        Exclusion Criteria:

          -  Body Mass Index (BMI) &gt; 36.0

          -  Pregnant or nursing (lactating) females, confirmed by a positive human chorionic
             gonadotropin (HCG) laboratory test or females contemplating pregnancy

          -  Participation in any interventional clinical trial within 35 days prior to first
             study medication dose administration on Day 1

          -  Known HIV-1 or HIV-2 infection/serology and/or positive Hepatitis B Surface Antigen
             (HBsAg)

          -  Use of dietary supplements, grapefruit juice, herbal supplements, CYP2C8 substrates,
             CYP3A4 inducers and inhibitors, PGP inducers and substrates, OATP inhibitors and
             substrates, and potent inducers of other CYP enzymes within 14 days prior to dosing
             through 7 days following completion of study meds.

          -  Clinically significant laboratory abnormality at screening (specified in protocol)

          -  Other forms of liver disease

          -  History of severe or uncontrolled psychiatric disease

          -  History of malignancy of any organ system, treated or untreated within the past 5
             years

          -  History of major organ transplantation

          -  Use of bone marrow colony stimulating factor agents within 3 months prior to
             baseline.

          -  History of seizure disorder requiring ongoing medical therapy

          -  History of known coagulopathy including hemophilia

          -  History of hemoglobinopathy, including sickle cell anemia and thalassemia.

          -  History of immunologically mediated disease (specified in protocol)

          -  History of clinical evidence of significant chronic cardiac disease ( specified in
             protocol)

          -  ECG with any clinically significant abnormality.

          -  Structural or functional cardiac abnormalities (specified in protocol)

          -  History of COPD, emphysema, or other chronic lung disease.

          -  Subjects currently abusing amphetamines, cocaine or opiates, or with ongoing alcohol
             abuse in the judgement of the investigator
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Franco Felizarta</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>eStudy Site</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Specialists of Georgia</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville Gastrointestinal Specialists</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver Associates of Texas PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Research Corporation</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Associates of Central Virginia</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Liver Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6H3M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 1, 2015</lastchanged_date>
  <firstreceived_date>April 18, 2013</firstreceived_date>
  <firstreceived_results_date>January 26, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C, Chronic</keyword>
  <keyword>Genotype 1</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Liver Diseases</keyword>
  <keyword>Hepatitis, viral, human</keyword>
  <keyword>ribavirin</keyword>
  <keyword>antiviral agents</keyword>
  <keyword>anti-infective agents</keyword>
  <keyword>protease inhibitors</keyword>
  <keyword>NS5a inhibitors</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
